Amedisys Reports Third Quarter 2021 Financial Results Updates 2021 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Amedisys (AMED) Tops Q3 EPS by $0.16
November 2, 2021 4:09 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $1.53, $0.16 better than the analyst estimate of $1.37. Revenue for the quarter came in at $553.5 versus the consensus estimate of $568.37 million.
GUIDANCE:
Amedisys sees FY2021 EPS of $5.88-$5.93, versus the consensus of $6.08. Amedisys sees FY2021... More
